A Randomized Trial of the IMPACT of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis

Ferric citrate (FC) is an FDA-approved iron-based phosphate binder for adults with dialysis-dependent chronic kidney disease. This study investigated the impact of FC as the primary phosphate-lowering therapy on utilization of erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron.